Regulation of human CYP2C9 by the constitutive androstane receptor:: Discovery of a new distal binding site

被引:130
作者
Ferguson, SS
Lecluyse, EL
Negishi, M
Goldstein, JA
机构
[1] NIEHS, Lab Pharmacol & Chem, Res Triangle Pk, NC 27709 USA
[2] NIEHS, Reprod & Dev Toxicol Lab, Res Triangle Pk, NC 27709 USA
[3] Univ N Carolina, Sch Pharm, Chapel Hill, NC USA
关键词
D O I
10.1124/mol.62.3.737
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The CYP2C subfamily metabolizes many clinically important drugs. These genes respond to prototypical inducers such as phenobarbital and rifampicin, yet little has been reported on the mechanisms of induction. This report examines the regulation of CYP2C9 with respect to two specific receptors thought to be involved in phenobarbital (PB) induction, the constitutive androstane receptor (CAR) and pregnane X receptor (PXR). Transfection of either mouse CAR (mCAR) or human CAR (hCAR) into HepG2 cells results in increased CYP2C9 mRNA content. Inducers further increased this response in CAR transfected cells. mCAR but not hCAR conferred drug inducibility to the proximal -2145 bp of the CYP2C9 promoter in luciferase assays. Further examination of a -2925-bp promoter construct revealed that hCAR cotransfection increased activity 20-fold. Gel shift assays confirmed the presence of a distal PB-responsive enhancer module-like enhancer module, CAR-responsive enhancer (CAR-RE), between -2900 and -2841 bp consisting of two DR-5 nuclear receptor binding motifs capable of binding hCAR, mCAR, and, to a lesser extent, human PXR. The majority of binding and hCAR activation is derived from the NR1 portion of the CAR-RE. PB treatment did not further increase the hCAR activation in any of the constructs. In summary, a new CAR/PXR binding site was identified in the CYP2C9 promoter, and this site seems to constitutively regulate transcription via a CAR-dependent mechanism; however, it could not be shown to account for PB inducibility of the gene.
引用
收藏
页码:737 / 746
页数:10
相关论文
共 32 条
  • [1] POLYMORPHIC HYDROXYLATION OF S-MEPHENYTOIN AND OMEPRAZOLE METABOLISM IN CAUCASIAN AND CHINESE SUBJECTS
    ANDERSSON, T
    REGARDH, CG
    LOU, YC
    ZHANG, Y
    DAHL, ML
    BERTILSSON, L
    [J]. PHARMACOGENETICS, 1992, 2 (01): : 25 - 31
  • [2] SXR, a novel steroid and xenobiotic-sensing nuclear receptor
    Blumberg, B
    Sabbagh, W
    Juguilon, H
    Bolado, J
    van Meter, CM
    Ono, ES
    Evans, RM
    [J]. GENES & DEVELOPMENT, 1998, 12 (20) : 3195 - 3205
  • [3] STEREOCHEMICAL ASPECTS OF WARFARIN DRUG-INTERACTIONS - USE OF A COMBINED PHARMACOKINETIC-PHARMACODYNAMIC MODEL
    CHAN, E
    MCLACHLAN, A
    OREILLY, R
    ROWLAND, M
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 56 (03) : 286 - 294
  • [4] Differential transactivation by two isoforms of the orphan nuclear hormone receptor CAR
    Choi, HS
    Chung, MR
    Tzameli, I
    Simha, D
    Lee, YK
    Seol, W
    Moore, DD
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (38) : 23565 - 23571
  • [5] DIXON JL, 1993, J LIPID RES, V34, P167
  • [6] Induction of drug metabolising enzymes - Pharmacokinetic and toxicological consequences in humans
    Fuhr, U
    [J]. CLINICAL PHARMACOKINETICS, 2000, 38 (06) : 493 - 504
  • [7] Transcriptional regulation of CYP2C9 gene -: Role of glucocorticoid receptor and constitutive androstane receptor
    Gerbal-Chaloin, S
    Daujat, M
    Pascussi, JM
    Pichard-Garcia, L
    Vilarem, MJ
    Maurel, P
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (01) : 209 - 217
  • [8] Gerbal-Chaloin S, 2001, DRUG METAB DISPOS, V29, P242
  • [9] BIOCHEMISTRY AND MOLECULAR-BIOLOGY OF THE HUMAN CYP2C SUBFAMILY
    GOLDSTEIN, JA
    DEMORAIS, SMF
    [J]. PHARMACOGENETICS, 1994, 4 (06): : 285 - 299
  • [10] Clinical relevance of genetic polymorphisms in the human CYP2C subfamily
    Goldstein, JA
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 52 (04) : 349 - 355